Skip to main content
SpringerLink
Log in

Adjuvante Therapie des Endometriumkarzinoms

Adjuvant therapy for endometrial carcinoma

  • Zum Thema
  • Published:
Der Gynäkologe Aims and scope

Zusammenfassung

Das Endometriumkarzinom im Stadium FIGO I/II hat nach adäquater chirurgischer Therapie (Hysterektomie mit beidseitiger Adnexexstirpation, systematische Lymphonodektomie) eine gute Prognose. Die Lymphonodektomie ist insbesondere bei Karzinomen mit ungünstigen Prognosefaktoren zu fordern. Eine adjuvante Chemotherapie mit 8 Zyklen Doxorubicin und Cisplatin bringt im Stadium III und IV einen Überlebensvorteil gegenüber einer adjuvanten perkutanen Radiotherapie. Kleine retrospektive Studien lassen einen Vorteil für eine adjuvante Chemotherapie im Stadium I/II bei ungünstigen Prognosefaktoren vermuten; randomisierte Studien dazu sind notwendig. Seröse und hellzellige Karzinome müssen eine konsequente, systematische chirurgische Therapie erhalten. Retrospektive Arbeiten weisen ebenfalls auf die Wirksamkeit einer adjuvanten Chemotherapie bei dieser histologischen Sonderform hin, lassen zurzeit aber keine valide Aussage zum adjuvanten Therapieregime zu.

Abstract

FIGO I/II endometrial carcinoma has a good prognosis after hysterectomy with bilateral extirpation of the appendages and lymphadenectomy, which is particularly important in cases with unfavourable prognostic factors. Adjuvant chemotherapy with eight cycles of doxorubicin and cisplatin leads to better survival in stage III and IV compared to adjuvant, percutaneous radiotherapy. Small retrospective studies suggest an advantage for adjuvant chemotherapy in stage I/II with unfavourable prognostic factors, however, randomized studies are still required. Serous and clear cell carcinoma require a thorough, systematic surgical therapy. Retrospective work also indicates the value of adjuvant chemotherapy for this particular histological form, although this is not sufficient to provide a valid statement on a regime for adjuvant therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Creasman WT, Odicino F, Maisonneuve P et al. (2003) Carcinoma of the corpus uteri. Int J Gynaecol Obstet (Suppl 1) 83: 79–118

    Article  Google Scholar 

  2. Aalders J, Abeler V, Kolstad P, Onsrud M (1980) Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 56: 419–427

    PubMed  Google Scholar 

  3. Creutzberg CL, van Putten WL, Koper PC et al. (2000) Surgery and postoperative radiotherapy vs. surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 355: 1404–1411

    Article  PubMed  Google Scholar 

  4. Keys HM, Roberts JA, Brunetto VL et al. (2004) A Phase-III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92: 744–751

    Article  PubMed  Google Scholar 

  5. Lee CM, Szabo A, Shrieve DC et al. (2006) Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma. JAMA 295: 389–397

    Article  PubMed  Google Scholar 

  6. Cragun JM, Havrilesky LJ, Calingaert B et al. (2005) Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol 23: 3668–3675

    Article  PubMed  Google Scholar 

  7. Kilgore LC, Partridge EE, Alvarez RD et al. (1995) Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol 56: 29–33

    Article  PubMed  Google Scholar 

  8. COSA-NZ-UK Endometrial Cancer Study Group (1996) Pelvic lymphadenectomy in high risk endometrial cancer. Int J Gynecol Cancer 6: 102–107

    Article  Google Scholar 

  9. Fanning J (2001) Long-term survival of intermediate risk endometrial cancer (stage IG3, IC, II) treated with full lymphadenectomy and brachytherapy without teletherapy. Gynecol Oncol 82: 371–374

    Article  PubMed  Google Scholar 

  10. Straughn JM, Huh WK, Orr JW Jr et al. (2003) Stage IC adenocarcinoma of the endometrium: survival comparisons of surgically staged patients with and without adjuvant radiation therapy. Gynecol Oncol 89: 295–300

    Article  PubMed  Google Scholar 

  11. Kitchener HC, Redman CW, Swart AMC, Amos CL (2005) ASTEC (Surgery component) A study in the treatment of endometrial cancer. A randomized trial of lymphadenectomy in the treatment of endometrial cancer (Abstract book). Int J Gynecol Cancer 15: 77

    Google Scholar 

  12. Scholten AN, van Putten WL, Beerman H et al. (2005) Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys 63: 834–838

    Article  PubMed  Google Scholar 

  13. Mariani A, Webb MJ, Keeney GL et al. (2002) Assessment of prognostic factors in stage IIIA endometrial cancer. Gynecol Oncol 86: 38–44

    Article  PubMed  Google Scholar 

  14. Kasamatsu T, Onda T, Katsumata N et al. (2003) Prognostic significance of positive peritoneal cytology in endometrial carcinoma confined to the uterus. Br J Cancer 88: 245–250

    Article  PubMed  Google Scholar 

  15. Mundt AJ, Murphy KT, Rotmensch J et al. (2001) Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinoma. Int J Radiat Oncol Biol Phys 50: 1154–1160

    Article  PubMed  Google Scholar 

  16. Creutzberg CL, van Putten WL, Warlam-Rodenhuis CC et al. (2004) Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol 22: 1234–1241

    Article  PubMed  Google Scholar 

  17. Mariani A, Dowdy SC, Cliby WA et al. (2006) Efficacy of systematic lymphadenectomy and adjuvant radiotherapy in node-positive endometrial cancer patients. Gynecol Oncol [Epub ahead of print]

  18. Havrilesky LJ, Cragun JM, Calingaert B et al. (2005) Resection of lymph node metastases influences survival in stage IIIC endometrial cancer. Gynecol Oncol 99: 689–695

    Article  PubMed  Google Scholar 

  19. Martin-Hirsch PL, Jarvis G, Kitchener H, Lilford R (2002) Progestagens for endometrial cancer. Cochrane Library, Oxford

  20. Carey MS, Gawlik C, Fung-Kee-Fung M et al. (2006) Systematic review of systemic therapy for advanced or recurrent endometrial cancer. Gynecol Oncol 101: 158–167

    Article  PubMed  Google Scholar 

  21. Humber C, Tierney J, Symonds P et al. (2005) Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev

  22. Deppe G (1982) Chemotherapeutic treatment of endometrial carcinoma. Clin Obstet Gynecol 25: 93–99

    Article  PubMed  Google Scholar 

  23. Cohen CJ (1986) Cytotoxic chemotherapy for patients with endometrial carcinoma. Clin Obstet Gynaecol 13: 811–824

    PubMed  Google Scholar 

  24. Thigpen JT, Brady MF, Homesley HD et al. (2004) Phase-III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 22: 3902–3908

    Article  PubMed  Google Scholar 

  25. Aapro MS, van Wijk FH, Bolis G et al. (2003) Doxorubicin vs. doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 14: 441–448

    Article  PubMed  Google Scholar 

  26. Fleming GF, Brunetto VL, Cella D et al. (2004) Phase-III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 22: 2159–2166

    Article  PubMed  Google Scholar 

  27. Fleming GF, Filiaci VL, Bentley RC et al. (2004) Phase-III randomized trial of doxorubicin + cisplatin vs. doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol 15: 1173–1178

    Article  PubMed  Google Scholar 

  28. Aoki Y, Watanabe M, Amikura T et al. (2004) Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer. Gynecol Oncol 94: 333–339

    Article  PubMed  Google Scholar 

  29. Burke TW, Gershenson DM, Morris M et al. (1994) Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy in women with high-risk endometrial carcinoma. Gynecol Oncol 55: 47–50

    Article  PubMed  Google Scholar 

  30. Kodama J, Seki N, Ojima Y et al. (2006) Efficacy and prognostic implications of administering adjuvant chemotherapy to patients with endometrial cancer that is confined to the uterus. Eur J Obstet Gynecol Reprod Biol [Epub ahead of print]

  31. Watari H, Todo Y, Takeda M et al. (2005) Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer. Gynecol Oncol 96: 651–657

    Article  PubMed  Google Scholar 

  32. Takeshima N, Umayahara K, Fujiwara K et al. (2006) Effectiveness of postoperative chemotherapy for para-aortic lymph node metastasis of endometrial cancer. Gynecol Oncol [Epub ahead of print]

  33. Randall ME, Filiaci VL, Muss H et al. (2006) Randomized Phase-III trial of whole-abdominal irradiation vs. doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 24: 36–44

    Article  PubMed  Google Scholar 

  34. Morrow CP, Bundy BN, Homesley HD et al. (1990) Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study. Gynecol Oncol 36: 166–171

    Article  PubMed  Google Scholar 

  35. Bristow RE, Zahurak ML, Alexander CJ et al. (2003) FIGO stage IIIC endometrial carcinoma: resection of macroscopic nodal disease and other determinants of survival. Int J Gynecol Cancer 13: 664–672

    Article  PubMed  Google Scholar 

  36. Onda T, Yoshikawa H, Mizutani K et al. (1997) Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy. Br J Cancer 75: 1836–1841

    PubMed  Google Scholar 

  37. Bruzzone M, Miglietta L, Franzone P et al. (2004) Combined treatment with chemotherapy and radiotherapy in high-risk FIGO stage III–IV endometrial cancer patients. Gynecol Oncol 93: 345–352

    Article  PubMed  Google Scholar 

  38. Smith MR, Peters WA 3rd, Drescher CW (1994) Cisplatin, doxorubicin hydrochloride, and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinoma. Am J Obstet Gynecol 170: 1677–1681

    PubMed  Google Scholar 

  39. Duska LR, Berkowitz R, Matulonis U et al. (2005) A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with „high-risk“ endometrial cancer. Gynecol Oncol 96: 198–203

    Article  PubMed  Google Scholar 

  40. Soper JT, Reisinger SA, Ashbury R et al. (2004) Feasibility study of concurrent weekly cisplatin and whole abdominopelvic irradiation followed by doxorubicin/cisplatin chemotherapy for advanced stage endometrial carcinoma: a Gynecologic Oncology Group trial. Gynecol Oncol 95: 95–100

    Article  PubMed  Google Scholar 

  41. Greven K, Winter K, Underhill K et al. (2006) Final analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol (in press)

    Google Scholar 

  42. McMeekin DS, Lashbrook D, Gold M et al. (2001) Analysis of FIGO Stage IIIc endometrial cancer patients. Gynecol Oncol 81: 273–278

    Article  PubMed  Google Scholar 

  43. Reisinger SA, Asbury R, Liao SY, Homesley HD (1996) A Phase-I study of weekly cisplatin and whole abdominal radiation for the treatment of stage III and IV endometrial carcinoma: a Gynecologic Oncology Group pilot study. Gynecol Oncol 63: 299–303

    Article  PubMed  Google Scholar 

  44. Katz LA, Andrews SJ, Fanning J (2001) Survival after multimodality treatment for stage IIIC endometrial cancer. Am J Obstet Gynecol 184: 1071–1073

    Article  PubMed  Google Scholar 

  45. Frigerio L, Mangili G, Aletti G et al. (2001) Concomitant radiotherapy and paclitaxel for high-risk endometrial cancer: first feasibility study. Gynecol Oncol 81: 53–57

    Article  PubMed  Google Scholar 

  46. Hendrickson M, Ross J, Eifel P et al. (1982) Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 6: 93–108

    PubMed  Google Scholar 

  47. Eifel PJ, Ross J, Hendrickson M et al. (1983) Adenocarcinoma of the endometrium. Analysis of 256 cases with disease limited to the uterine corpus: treatment comparisons. Cancer 52: 1026–1031

    Article  PubMed  Google Scholar 

  48. Geisler JP, Sorosky JI, Duong HL et al. (2001) Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinoma. Gynecol Oncol 83: 501–503

    Article  PubMed  Google Scholar 

  49. Elit L, Pal T, Goshen R et al. (2002) Familial and hormonal risk factors for papillary serous uterine cancer. Eur J Gynaecol Oncol 23: 187–190

    PubMed  Google Scholar 

  50. Slomovitz BM, Burke TW, Eifel PJ et al. (2003) Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol 91: 463–469

    Article  PubMed  Google Scholar 

  51. Goff BA, Kato D, Schmidt RA et al. (1994) Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 54: 264–268

    Article  PubMed  Google Scholar 

  52. Boruta DM 2nd, Gehrig PA, Groben PA et al. (2004) Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference? Cancer 101: 2214–2221

    Article  PubMed  Google Scholar 

  53. Bristow RE, Asrari F, Trimble EL, Montz FJ (2001) Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I-III) disease. Gynecol Oncol 81: 279–286

    Article  PubMed  Google Scholar 

  54. Chan JK, Loizzi V, Youssef M et al. (2003)Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium. Gynecol Oncol 90: 181–185

    Article  PubMed  Google Scholar 

  55. Podratz KC, Mariani A (2003) Uterine papillary serous carcinomas: the exigency for clinical trials. Gynecol Oncol 91: 461–462

    Article  PubMed  Google Scholar 

  56. Bristow RE, Duska LR, Montz FJ (2001) The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma. Gynecol Oncol 81: 92–99

    Article  PubMed  Google Scholar 

  57. Elit L, Kwon J, Bentley J et al. (2004) Optimal management for surgically Stage 1 serous cancer of the uterus. Gynecol Oncol 92: 240–246

    Article  PubMed  Google Scholar 

  58. Hamilton CA, Cheung MK, Osann K et al. (2006) Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 94: 642–646

    PubMed  Google Scholar 

  59. Kelly MG, O’malley DM, Hui P et al. (2005) Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol 98: 353–359

    Article  PubMed  Google Scholar 

  60. Huh WK, Powell M, Leath CA 3rd et al. (2003) Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. Gynecol Oncol 91: 470–475

    Article  PubMed  Google Scholar 

  61. Ramondetta L, Burke TW, Levenback C et al. (2001) Treatment of uterine papillary serous carcinoma with paclitaxel. Gynecol Oncol 82: 156–161

    Article  PubMed  Google Scholar 

  62. Zanotti KM, Belinson JL, Kennedy AW et al. (1999) The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma. Gynecol Oncol 74: 272–277

    Article  PubMed  Google Scholar 

  63. Vaidya AP, Littell R, Krasner C, Duska LR (2006) Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel. Int J Gynecol Cancer (Suppl 1) 16: 267–272

    Article  Google Scholar 

  64. Sutton G, Axelrod JH, Bundy BN et al. (2005) Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study. Gynecol Oncol 97: 755–763

    Article  PubMed  Google Scholar 

  65. Dietrich CS 3rd, Modesitt SC, DePriest PD et al. (2005) The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC). Gynecol Oncol 99: 557–563

    Article  PubMed  Google Scholar 

  66. Low JS, Wong EH, Tan HS et al. (2005) Adjuvant sequential chemotherapy and radiotherapy in uterine papillary serous carcinoma. Gynecol Oncol 97: 171–177

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.

Author information

Authors and Affiliations

  1. Universitätsfrauenklinik, Universität Duisburg-Essen, 45122, Hufelandstraße 55, Essen, Deutschland

    C. Böing & R. Kimmig

Authors
  1. C. Böing
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Kimmig
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Böing.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Böing, C., Kimmig, R. Adjuvante Therapie des Endometriumkarzinoms. Gynäkologe 40, 34–43 (2007). https://doi.org/10.1007/s00129-006-1931-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00129-006-1931-1

Schlüsselwörter

Keywords

Search

Navigation